Image from Yasheng Pharmaceuticals official website On July 18, 2018, Arterial Network learned that Yasheng Pharmaceutical, the world's leading research and development company focused on the research of apoptosis, has successfully completed a billion-yuan (about US$150 million) Series C financing. This round of financing was led by Yuanming Fangyuan Fund. Yuanhe Origin and Tengyue Fund jointly led the investment, and ArrowMark Partners, HDY International Investment, Qingsong Capital and CCB International jointly voted. So far, the company has raised a total of 240 million US dollars. Founded in 2010, Yasheng Pharmaceutical is a leading global innovative pharmaceutical research and development company founded by three national “Thousand Talents†experts. The company aims to develop a new internationally-originated small molecule drug with the potential of “First-in-Class†or “Best-in-Classâ€, aiming at the clinical needs of “no medicine, no treatment†in China and the world. Its core team is one of the first in the world to enter new targets for the development of small molecule inhibitors of apoptotic pathways. At the same time, it ranks first in the world in the field of protein-protein interactions of high-tech barriers, and the corresponding drug development is in this field. International leadership. The company has successfully completed product strategic layout in three major therapeutic areas: tumor, hepatitis B and aging-related diseases. The product targets include apoptosis and autophagy dual-channel regulation of new targets Bcl-2, IAP and MDM2-p53. It also includes clinically validated mature targets ALK, Bcr-Abl and c-Met. After receiving 500 million yuan of B round of financing at the end of 2016, Yasheng Pharmaceutical accelerated the clinical development of the product line. Now seven original innovative drugs have entered the clinical stage of I-II in China, the United States and Australia. It is understood that this round of financing will be used for the further comprehensive expansion of the company's clinical product development and the construction of industrial bases. “We are very pleased that this round of financing can be continuously recognized and supported by many investment institutions.†Dr. Yang Dajun, Chairman of Yasheng Pharmaceutical, said. Yasheng currently has 7 products and has obtained a total of 16 clinical approvals. Among them, 8 were approved for clinical approval in China, 5 were approved by the US FDA, and 3 were obtained in Australia. The company is entering a comprehensive development phase of clinical product development, and the participation of well-known biomedical industry funds will further assist in the construction of our clinical development and industrialization base. “As the only company in the field of apoptosis that has been deployed with multiple product line combinations, we expect Yasheng Pharmaceutical to accelerate development with investors, develop and produce more effective and safe original innovative drugs for patients in China and around the world. Provide more effective treatment options," he continued. One of the leading investors, Yuanming Fangyuan Fund, was founded by entrepreneurs and senior financial and pharmaceutical investment experts who are familiar with the Chinese mainland, Hong Kong and the US market. The fund focuses on cross-border investment companies investing in advanced research and development, innovative medical device development, and advanced medical services in China and the United States. Dr. Tian Yuan, Chairman of Yuanming Fangyuan Fund, said: “Yuanming Fangyuan Fund is focused on investing in outstanding enterprises in the medical and health industry. We continue to be optimistic about the great development potential of Yasheng Pharmaceutical in the field of apoptosis. We look forward to further close cooperation with Yasheng Pharmaceutical. To promote the company's development, and help the company further promote the clinical development of core products in the United States, China and Australia, and achieve product launch as soon as possible." Yuanhe Origin is a member company of Suzhou Yuanhe Holdings Co., Ltd. It is a professional early stage equity investment platform for market operation, focusing on investment opportunities for start-up and growth startups in the two major areas of medical health and TMT. Yuanhe origin has rich experience and excellent brand influence in the field of medical and health. Zhao Qun, a partner of Yuanhe Origin, said: "We are very optimistic about the innovative research and industry leadership position of Yasheng Pharmaceutical in the field of protein-protein interaction. Yasheng Pharmaceutical is aiming at the demand of 'no medicine can cure', thus benefiting patients and the whole society." He believes that Yasheng Pharmaceutical will one day have a place in world-class biopharmaceutical companies based on Yasheng's strong clinical R&D pipeline and fully functional management team. Respiratary System,Doxofylline And Glucose Injection,Doxofylline And Glucose Solution,Doxofylline And Glucose Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com